Por favor, use este identificador para citar o enlazar este ítem: 10.1039/D2FO00552B

Título: Urolithins: potential biomarkers of gut dysbiosis and disease stage in Parkinson's patients
Fecha de publicación: 28-abr-2022
Editorial: The Royal Society of Chemistry
Cita bibliográfica: Food Funct., 2022, 13, 6306-6316
Materias relacionadas: CDU::6 - Ciencias aplicadas::61 - Medicina
Palabras clave: Parkinson's Disease
Resumen: Gut microbiota alteration (gut dysbiosis) occurs during the onset and progression of Parkinson's disease. Gut dysbiosis biomarkers could be relevant to prodromal disease. Urolithins, anti-inflammatory metabolites produced from some dietary polyphenols by specific gut microbial ecologies (urolithin metabotypes), have been proposed as biomarkers of gut microbiota composition and functionality. However, this has not been explored in Parkinson's disease patients. The current study aimed to assess associations between urolithin metabotypes, gut dysbiosis and disease severity in Parkinson's disease patients. Participants (52 patients and 117 healthy controls) provided stool samples for microbiota sequencing and urine samples for urolithin profiling before and after consuming 30 g of walnuts for three days. Data on demographics, medication, disease duration and Hoehn and Yahr disease stage were collected. We observed a significant gradual increase of urolithin non-producers (metabotype-0) as the disease severity increased. The gut microbiome of metabotype-0 patients and patients with the greatest severity was characterized by a more altered bacterial composition, i.e., increased pro-inflammatory Enterobacteriaceae and reduced protective bacteria against autoimmune and inflammatory processes, including butyrate and urolithin-producing bacteria (Lachnospiraceae members and Gordonibacter). Besides, their microbiome was characterized by predictive functions of lipopolysaccharide biosynthesis and metabolism of glutathione, cysteine and methionine that could indirectly reflect the gut pro-inflammatory status. Urolithin detection in urine is a feasible, non-invasive and fast approach that can reflect gut microbiome dysbiosis and intestinal inflammation in Parkinson's disease patients. Our current study could provide novel strategies for improving diagnostics, and for preventing and treating disease progression in microbiota-based interventions.
Autor/es principal/es: Romo Vaquero, María
Fernández Villalba, Emiliano
Gil Martínez, Ana Luisa
Cuenca Bermejo, Lorena
Espín de Gea, Juan Carlos
Herrero Ezquerro, María Trinidad
Selma García, María Victoria
Versión del editor: https://pubs.rsc.org/en/content/articlehtml/2022/fo/d2fo00552b
URI: http://hdl.handle.net/10201/139090
DOI: 10.1039/D2FO00552B
Tipo de documento: info:eu-repo/semantics/article
Número páginas / Extensión: 11
Derechos: info:eu-repo/semantics/openAccess
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Descripción: Open Access Article This Open Access Article is licensed under a Creative Commons Attribution-Non Commercial 3.0 Unported Licence
Aparece en las colecciones:Artículos: Anatomía Humana y Psicobiología

Ficheros en este ítem:
Fichero Descripción TamañoFormato 
2022 Urolithins- potential biomarkers of gut dysbiosis and disease stage in Parkinson’s patients.pdf4,45 MBAdobe PDFVista previa
Visualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons